Yahoo Finance: More Patients Open to Non-GLP-1 Obesity Treatments After Learning About Alternatives, Phenomix Survey Finds Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today released new findings from its "2026 State of Obesity Treatment Report: Progress, Gaps, and ... More Patients Open to Non-GLP-1 Obesity Treatments After Learning About Alternatives, Phenomix Survey Finds New York Post: Pfizer amps up push into obesity treatments with $4.9B deal with Metasera Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...
Pfizer amps up push into obesity treatments with $4.9B deal with Metasera Medical Xpress: Obesity, treatment, and shame: What women really think about pharmacotherapy The Cincinnati Enquirer: Salta Direct Announces New Employer Initiative to Expand Access to Obesity Treatment Salta Direct Announces New Employer Initiative to Expand Access to Obesity Treatment The Print on MSN: Genes decide who responds better to GLP-1 drugs. How Nature study findings can change obesity treatment Genes decide who responds better to GLP-1 drugs. How Nature study findings can change obesity treatment The American Journal of Managed Care: Shawn Davis, MD, on How Payers Should Think About Obesity Treatment Return on Investment With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it. One of the most pressing financial debates in ...
obesity treatment, Shawn Davis, MD, on How Payers Should Think About Obesity Treatment Return on Investment
